Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

A 2-Stage, Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older

This is a 2-Stage, Phase III, randomized, active-controlled, observer-blind, parallel-group, multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03 (GBP510) to ChAdOx1-S in adults aged 18 years and older.

Study Overview

• Status: Completed
• Conditions: Covid19
• Intervention / Treatment: Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); Biological: ChAdOx1-S not less than 2.5 × 10^8 infectious units

Detailed Description

The purpose of this study is to assess the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03 (GBP510) in adults aged 18 years and older.

This study includes 2-dose schedule (28-day interval) of GBP510(Test vaccine) and ChAdOx1-S(Control vaccine) in stage1. Participants are expected to participate for up to a maximum of approximately 13 months. A 12-month study follow-up after the 2nd vaccination will be conducted. One booster dose of GBP510 is scheduled for both test group and control group in Stage2. A 12-month study follow-up after the 3rd vaccination will be conducted.

International Vaccine Institute (IVI) conducts GBP510_003 trial as co-sponsor with SK bioscience.

• Study Type: Interventional
• Enrollment (Actual): 4036
• Phase: Phase 3

Contacts and Locations

Study Locations

• Korea, Republic of
  • Busan, Korea, Republic of
    • Dong-A University Hospital
  • Daegu, Korea, Republic of
    • Kyungpook National University Hospital
  • Daegu, Korea, Republic of
    • Kyungpook National University Chilgok Hospital
  • Gwangju, Korea, Republic of
    • Chonnam National University Hospital
  • Incheon, Korea, Republic of
    • Inha University Hospital
  • Incheon, Korea, Republic of
    • Gachon University Gil Medical Center
  • Seoul, Korea, Republic of
    • Korea University Guro Hospital
  • Seoul, Korea, Republic of
    • Severance Hospital
  • Seoul, Korea, Republic of
    • Korea University Anam Hospital
  • Seoul, Korea, Republic of
    • Ewha womans university medical center
  • Seoul, Korea, Republic of, 04401
    • Soonchunhyang University Hospital
  • Seoul, Korea, Republic of
    • Hallym University Medical Center
  • Seoul, Korea, Republic of, 03080
    • Seoul national university hosptial
  • Wonju, Korea, Republic of
    • Wonju Severance Christian Hospital
  • Gyeonggi
    • Ansan, Gyeonggi, Korea, Republic of
      • Korea University Ansan Hostpital
    • Suwon, Gyeonggi, Korea, Republic of
      • Ajou University Hospital
• New Zealand
  • Auckland, New Zealand
    • Southern Clinicaltrials Waitemata
  • Christchurch, New Zealand
    • Southern Clinical Trials Christchurch
  • Hamilton, New Zealand
    • Lakeland Clinicaltrials Waikato
  • Nelson, New Zealand
    • Southern Clinical Trials Tasman
  • Papamoa, New Zealand
    • Lakeland Clinicaltrials Culloden
  • Rotorua, New Zealand
    • Lakeland Clinicaltrials Rotorua
  • Upper Hutt, New Zealand
    • Lakeland Clinicaltrials Wellington
• Philippines
  • Manila, Philippines
    • San Francisco Multi-Purpose Building
  • Manila, Philippines
    • University of the East-Ramon Magsaysay Memorial Medical Center Inc.
  • Quezon City, Philippines
    • Health Index Multispeciality Clinic
• Thailand
  • Bangkok, Thailand
    • Siriraj Hospital
  • Bangkok, Thailand
    • Armed Forces Research Institute of Medical Sciences
  • Chiang Mai, Thailand
    • Maharaj Nakorn Chiang Mai Hospital
  • Khon Kaen, Thailand
    • Sriganarind Hospital
• Ukraine
  • Dnipro, Ukraine
    • Treatment and Diagnostic Center of LLC Treatment and Diagnostic Center Adonis Plus
  • Kropyvnytskyi, Ukraine
    • Medical and Diagnostic Сеntег of Рrivatе Еntеrрrisе of Рrivatе Manufacturing Соmрапу Acinus
  • Kyiv, Ukraine
    • Communal non-profit enterprise Kyiv City Clinical Hospital №6
  • Kyiv, Ukraine
    • Medical Center "Ok!Clinic+" of International Institute of Clinical Research LLC
  • Kyiv, Ukraine
    • Municipal Nonprofit Enterprise "Khmelnytsky Regional Hospital for War Veterans" of Khmelnytsky Regional Council
  • Odesa, Ukraine
    • Private Clinic LLC Blagomed
  • Dnipropetrovs'k
    • Dniprodzerzhyns'k, Dnipropetrovs'k, Ukraine
      • Medical center "Preventclinic" LLC
• Vietnam
  • Hochiminh city, Vietnam
    • Pasteur Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Participant must be 18 years of age and older, at the time of signing the informed consent;
• Participants who are healthy or medically stable as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and medical judgement of the investigator;
• Participants who are able to attend all scheduled visits and comply with all study procedures;
• Female participants of childbearing potential must agree to be heterosexually inactive, or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last study vaccination;
• Female participants with a negative urine or serum pregnancy test at screening;
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol;

<Stage2>

• Participants who have received 2 doses of GBP510 25μg adjuvanted with AS03 or ChAdOx1-S and have blood samples until Visit 7 in Stage 1
• Participants who received a primary series of GBP510 or ChAdOx1-S at least 12 weeks prior to booster vaccination in Stage 2
• Participants who are able to attend all additionally scheduled visits and comply with all study procedures.
• Female participants of childbearing potential must agree to be heterosexually inactive, or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the booster dose (3rd study vaccination) to 12 weeks after the booster dose
• Female participants with a negative urine or serum pregnancy test prior to the booster dose (the third dose of study vaccine)
• Capable of giving an informed consent for Stage 2 study in compliance with the requirements and restrictions listed in the informed consent form (ICF) for Stage 2 and in this protocol.

Exclusion Criteria:

• Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile illness (tympanic temperature >38°C), or acute illness within 72 hours prior to the 1st study vaccination. A prospective participant should not be included until 72 hours after the condition has resolved;
• (Only for Cohort 1) Prior SARS-CoV-2 infection or vaccination confirmed by a positive result of qualitative test for SARS-CoV-2 antibody using a rapid antibody kit at screening;
• History of virologically-confirmed SARS or MERS disease, or SARS / MERS vaccination;
• History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease;
• History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination;
• History of hypersensitivity and severe allergic reaction (e.g., anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study vaccine;
• History of malignancy within 1 year prior to the 1st study vaccination (with the exception of malignancy with minimal risk of recurrence at the discretion of the investigator);
• Significant unstable chronic or acute illness that, in the opinion of the investigator, might pose a health risk to the participant if enrolled, or could interfere with the protocol-specified activities, or interpretation of study results;
• Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or psychiatric conditions);
• Female participants who are pregnant or breastfeeding;
• Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned receipt of any vaccine from enrollment through 28 days after the last study vaccination (Visit 7), except for influenza vaccination, which may be received at least 2 weeks prior to the 1st study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines;
• Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to the 1st study vaccination;
• Receipt of any medications or vaccinations intended to prevent COVID-19;
• Chronic use (more than 2 consecutive weeks) of immunosuppressive therapy, such as anticancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within 12 weeks prior to the 1st vaccination. The use of topical and nasal glucocorticoids will be permitted;
• Participation in another clinical study involving study intervention within 4 weeks prior to the 1st study vaccination, or concurrent, planned participation in another clinical study with study intervention during the study period.
• Participants who are subjected to any global or local restrictions in place for use of ChAdOx1-S (e.g. age, gender, or other specific population groups)
• Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.

<Stage2>

• Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile illness (tympanic temperature >38°C), or acute illness within 72 hours prior to the booster dose (3rd study vaccination). A prospective participant should not be included until 72 hours after the condition has resolved.
• History of confirmed COVID-19, SARS or MERS disease confirmed by serological, virological assay, or rapid antigen kit
• Receipt of any medications or vaccinations intended to prevent COVID-19 except for GBP510 or ChAdOx1-S.
• Receipt of any vaccine within 4 weeks prior to the booster vaccination or planned receipt of any vaccine from enrollment through 28 days after the booster vaccination (Visit 4B), except for influenza vaccination, which may be received at least 2 weeks prior to the booster vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines
• Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to the booster vaccination
• Chronic use (more than 2 consecutive weeks) of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within 12 weeks prior to the booster vaccination. The use of topical and nasal glucocorticoids will be permitted.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test group (GBP510) - Cohort 1; Immunogenicity Cohort	Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 and 28 (stage1); Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 (stage2)
Active Comparator: Control group (ChAdOx1-S) - Cohort 1; Immunogenicity Cohort	Biological: ChAdOx1-S not less than 2.5 × 10^8 infectious units; injection volume of 0.5mL on days 0 and 28 (stage1)
Experimental: Test group (GBP510) - Cohort 2; Safety Cohort	Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 and 28 (stage1); Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 (stage2)
Active Comparator: Control group (ChAdOx1-S) - Cohort 2; Safety Cohort	Biological: ChAdOx1-S not less than 2.5 × 10^8 infectious units; injection volume of 0.5mL on days 0 and 28 (stage1)
Experimental: Test group (GBP510) - Cohort 3; Booster Subcohort	Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 and 28 (stage1); Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 (stage2)
Active Comparator: Control group (ChAdOx1-S) - Cohort 3; Booster Subcohort	Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 and 28 (stage1); Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose); injection volume of 0.5mL on days 0 (stage2)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays	For Cohort 1	2 weeks post 2nd vaccination
Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline	For Cohort 1	2 weeks post 2nd vaccination
Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays	For Cohort 3	2 weeks post 3rd (booster) and 2nd vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
GMT of SARS-CoV-2 Receptor-Binding Domain(RBD)-binding IgG antibody measured by Enzyme-Linked Immunosorbent Assay (ELISA) at each time point post-vaccination	For Cohort 1	Through Day 365 post last vaccination
Geometric Mean Fold Rise(GMFR) of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA from baseline	For Cohort 1	Through Day 365 post last vaccination
Percentage of participants with ≥ 4-fold rise SARS-CoV-2 RBD-binding IgG titer from baseline	For Cohort 1	Through Day 365 post last vaccination
GMT of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays	For Cohort 1	Through Day 365 post last vaccination
GMFR of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays from baseline	For Cohort 1	Through Day 365 post last vaccination
Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline	For Cohort 1	Through Day 365 post last vaccination
Cell-mediated response for both Th1 and Th2 cytokines measured by Enzyme-Linked ImmunoSpot (ELISpot)/ FluoroSpot, and for both CD4+ and CD8+ T-cells measured by Fluorescence-activated cell sorting(FACS)	For Cohort 1	Through Day 365 post last vaccination
Occurrence of immediate systemic reactions in the 30 minutes post each vaccination	For all Cohort	Through 30 minutes post each vaccination
Occurrence of solicited local Adverse Events(AEs)	For all Cohort	Through 7 days post each vaccination
Occurrence of solicited systemic AEs	For all Cohort	Through 7 days post each vaccination
Occurrence of unsolicited AEs	For all Cohort	Through 28 days post each vaccination
Occurrence of Serious Adverse events(SAEs), Medically attended Adverse Events(MAAEs), AEs leading to study withdrawal, and Adverse Events of Special Interests(AESIs)	For all Cohort	Through Day 365 post last vaccination
GMTs of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays	For Cohort 3	2 weeks post 3rd (booster) and 2nd vaccination
Percentages of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline (Visit 2)	For Cohort 3	2 weeks post 3rd (booster) and 2nd vaccination
GMTs of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays	For Cohort 3	pre (Visit 1B) and 2 weeks post 3rd (booster) vaccination
GMTs of neutralizing antibody to the SARS-CoV-2 measured by neutralization assays	For Cohort 3	2 weeks post 3rd (booster) and 2nd vaccination
GMT of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA at each time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
GMFR of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA from baseline (Visit 2) to each subsequent time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
GMFR of SARS-CoV-2 RBD-binding IgG antibody measured by ELISA from prior to booster vaccination (Visit 1B) to each subsequent time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
Percentage of participants with ≥4-fold rise in ELISA SARS-CoV-2 RBD-binding IgG titer from baseline (Visit 2) to each subsequent time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
Percentage of participants with ≥4-fold rise in ELISA SARS-CoV-2 RBD-binding IgG titer from pre-booster vaccination (Visit 1B) to each subsequent time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
GMT of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay at each time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
GMFR of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay from baseline (Visit 2) to each subsequent time point post booster vaccination.	For Cohort 3	Through Day 365 post last vaccination
GMFR of neutralizing antibody to SARS-CoV-2 measured by wild-type virus neutralization assay from prior to booster vaccination (Visit 1B) to each subsequent time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
Percentage of participants with ≥4-fold rise in wild-type virus neutralizing antibody titer to SARS-CoV-2 from baseline (Visit 2) to each subsequent time point post booster vaccination.	For Cohort 3	Through Day 365 post last vaccination
Percentage of participants with ≥4-fold rise in wild-type virus neutralizing antibody titer to SARS-CoV-2 from pre-booster vaccination (Visit 1B) to each subsequent time point post booster vaccination	For Cohort 3	Through Day 365 post last vaccination
Cell-mediated response for both Th1 and Th2 cytokines (including but not limited to INF-γ, TNF-α, IL-2, and IL-4 produced by T lymphocytes) measured by ELISpot and/or FluoroSpot, and for both CD4+ and CD8+ T-cells measured by FACS	For Cohort 3	Through Day 365 post last vaccination

Collaborators and Investigators

• Sponsor: SK Bioscience Co., Ltd.
• Collaborators: GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness Innovations
• Investigators: Principal Investigator: Hee Jin Cheong, Korea University Guro Hospital

Publications and helpful links

General Publications

• Walls AC, VanBlargan LA, Wu K, Choi A, Navarro MJ, Lee D, Avena L, Berrueta DM, Pham MN, Elbashir S, Kraft JC, Miranda MC, Kepl E, Johnson M, Blackstone A, Sprouse K, Fiala B, O'Connor MA, Brunette N, Arunachalam PS, Shirreff L, Rogers K, Carter L, Fuller DH, Villinger F, Pulendran B, Diamond MS, Edwards DK, King NP, Veesler D. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. Cell Rep. 2022 Aug 30;40(9):111299. doi: 10.1016/j.celrep.2022.111299. Epub 2022 Aug 15.

Study record dates

Study Major Dates

• Study Start (Actual): August 30, 2021
• Primary Completion (Actual): October 2, 2023
• Study Completion (Actual): October 2, 2023

Study Registration Dates

• First Submitted: August 9, 2021
• First Submitted That Met QC Criteria: August 9, 2021
• First Posted (Actual): August 17, 2021

Study Record Updates

• Last Update Posted (Actual): April 8, 2024
• Last Update Submitted That Met QC Criteria: April 5, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: GBP510_003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No